| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
EIPA is a novel and potent blocker of Na+/H+ antiport and an inhibitor of TRPP3 channel with an IC50 of 10.5 μM.
| Targets |
|
|
|---|---|---|
| ln Vitro |
In X, EIPA (100 μM, 30 min) inhibits the Ca2+ uptake mediated by TRPP3. Ovum laevis [1]. The basal Na+ current is reversibly inhibited by EIPA hydrochloride (10-100 μM) (IC50: 19.5 μM)[1]. In IEC-18 cells, EIPA (300 μM, 6 h) increases autophagy via NHE3 (Na+/H+-exchanger 3)[2]. EIPA (20 μM, 2 h) inhibits the large absorption of CA-PZ via macropinocytosis in both MIA PaCa-2 and HT-29 cells[3]. Zinc/kainate toxicity is attenuated by EIPA (30 μM, 3h) by reducing Zn2+ entrance in cerebellar granule neurons[4]. EIPA (5-100 μM, 48h) inhibits MKN28 cell growth by upregulating p21 expression[5]. The increase in COX-2 protein level generated by LPS is inhibited by EIPA (3 μM, 6 h)[7].
|
|
| ln Vivo |
EIPA (intravenous injection, 1 mg/kg) dose-dependently reduces I/R (ischemia/reperfusion)-induced renal dysfunction in ddY strain mice [6]. EIPA (orally, 10 mg/kg) inhibits LPS-induced inflammation in a balloon-type LPS-induced inflammation model [7].
|
|
| Enzyme Assay |
Methods: Effects of EIPA on proliferation, pH(c), [Cl(-)](c) and expression of proteins regulating cell cycle and MAPKs were studied in MKN28 expressing NHE exposed to EIPA for 48 h.
Results: EIPA suppressed proliferation of MKN28 cells by causing G(0)/G(1) arrest without any significant effects on pH(c), but associated with reduction of [Cl(-)](c). Although EIPA alone had no effects on pH(c), EIPA co-applied with DIDS (an inhibitor of Cl(-)/HCO(3)(-) exchangers; i.e., anion exchanger (AE) and Na+-driven Cl(-)/HCO(3)(-) exchanger (NDCBE)) reduced pH(c), suggesting that DIDS-sensitive Cl(-)/HCO(3)(-) transporters such as AE and/or NDCBE keep pH(c) normal by stimulating HCO(3)(-) uptake coupled with Cl(-) release under an NHE-inhibited condition. EIPA-induced lowered [Cl(-)](c) up-regulated expression of p21associated with phosphorylation of MAPKs, suppressing proliferation associated with G(0)/G(1) arrest.
Conclusions: EIPA suppressed proliferation of MKN28 cells through up-regulation of p21 expression via reduction of [Cl(-)](c) as a result from DIDS-sensitive Cl(-)/HCO(3)(-) exchanger-mediated compensation for keeping pH(c) normal under an NHE-inhibited condition. This is the first study revealing that an NHE inhibitor suppressed the proliferation of cancer cells by reducing [Cl(-)](c) but not pH(c)[5].
|
|
| Cell Assay |
Cell Proliferation Assay[5]
Cell Types: MKN28 cells Tested Concentrations: 5, 10, 25, 50, and 100 μM Incubation Duration: 48 h Experimental Results: Inhibited cell proliferation in a dose- and time-dependent manner. Western Blot Analysis[2] Cell Types: IEC-18 cells Tested Concentrations: 300 μM Incubation Duration: 6 h Experimental Results: Increased total LC3-II protein levels and P62 flux. Increased ATG5, 7, 12 and P62 expression. |
|
| Animal Protocol |
Animal/Disease Models: Male ddY strain mouse [6]
Doses: 1 mg/kg Route of Administration: intravenous (iv) (iv)injection Experimental Results: Reduce histological renal damage and improve the increase in renal ET-1 content caused by I/R. Animal/Disease Models: air bag type LPS-induced inflammation model [7] Doses: 10 mg/kg Route of Administration: Oral Experimental Results:Inhibited LPS-induced leukocyte infiltration into air bags. Suppresses the amount of PGE2 in ostomy bag fluid. |
|
| References | ||
| Additional Infomation |
Ethylisopropylamiloride is a member of the class of pyrazines that is amiloride in which the amino substitutent of the pyrazine ring that is adjacent to the chloro substituent has been substituted by an ethyl group and by an isopropyl group. It has a role as an anti-arrhythmia drug, a neuroprotective agent and a sodium channel blocker. It is a member of guanidines, an aromatic amine, an organochlorine compound, a tertiary amino compound, a member of pyrazines and a monocarboxylic acid amide. It is functionally related to an amiloride.
|
| Molecular Formula |
C11H18CLN7O
|
|---|---|
| Molecular Weight |
299.76
|
| Exact Mass |
299.126
|
| Elemental Analysis |
C, 44.08; H, 6.05; Cl, 11.83; N, 32.71; O, 5.34
|
| CAS # |
1154-25-2
|
| Related CAS # |
EIPA hydrochloride;1345839-28-2
|
| PubChem CID |
1795
|
| Appearance |
Typically exists as White to yellow solids at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
543.9±60.0 °C at 760 mmHg
|
| Melting Point |
202-205ºC(lit.)
|
| Flash Point |
282.8±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.665
|
| LogP |
4.86
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
372
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=NC(Cl)=C(N(CC)C(C)C)N=C1N)NC(N)=N
|
| InChi Key |
QDERNBXNXJCIQK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H18ClN7O/c1-4-19(5(2)3)9-7(12)16-6(8(13)17-9)10(20)18-11(14)15/h5H,4H2,1-3H3,(H2,13,17)(H4,14,15,18,20)
|
| Chemical Name |
3-amino-6-chloro-N-(diaminomethylidene)-5-[ethyl(propan-2-yl)amino]pyrazine-2-carboxamide
|
| Synonyms |
Ethyl isopropylamiloride; EIPA; 1154-25-2; 5-(N-Ethyl-N-isopropyl)amiloride; Ethylisopropylamiloride; 5-(Ethylisopropyl)amiloride; Ethyl isopropyl amiloride; 5-(N-Ethyl-N-isopropyl) Amiloride; 5-(N-ethyl-N-isopropyl)-Amiloride;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~166.80 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3360 mL | 16.6800 mL | 33.3600 mL | |
| 5 mM | 0.6672 mL | 3.3360 mL | 6.6720 mL | |
| 10 mM | 0.3336 mL | 1.6680 mL | 3.3360 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
